{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-399383","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2026-09-23T20:06:24+00:00","discovered_at":"2026-09-23T20:07:10.776095+00:00","generated_at":"2026-09-23T20:09:05.076324+00:00","sec_items":["1.01","2.01","2.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Zymeworks closes $17/share Theravance acquisition; issues $350M notes","bullets":["Zymeworks completes Theravance merger; each share converted to $17.00 cash plus one CVR.","CVR pays 80% of ampreloxetine license proceeds, $50M U.S./EU first-commercial-sale milestone, 10% net sales.","Issued $350M senior secured notes at 8.25% fixed rate, maturing Dec 31, 2036, to OMERS-affiliated purchaser.","Notes guaranteed by four Theravance IP subsidiaries; proceeds funded cash consideration and CVR payments.","Investor call scheduled Sept 28, 2026, 8:30 a.m. ET to discuss closing details."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-399383","json":"https://secwatch.observer/filing/0001193125-26-399383.json","markdown":"https://secwatch.observer/filing/0001193125-26-399383.md","text":"https://secwatch.observer/filing/0001193125-26-399383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000119312526399383/0001193125-26-399383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000119312526399383/d270232d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-23T20:09:05.076324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}